

Changes to New Zealand's Plasma Products from 2023 to 2025



CSL Behring, who manufacture our **plasma products**, have been investing in new facilities at their manufacturing site at Broadmeadows, Victoria.



Within these new facilities, **five of New Zealand's domestic plasma products** will now be manufactured using CSL Behring's global manufacturing processes.




As per the current products, the transitioned products will comply with the **SAFETY** and **EFFICACY** requirements set by the Therapeutic Goods Administration and will go through the New Medicines Approval process with Medsafe.



Products will be changed in a staged way over **the next three years**.

The product transitions are shown in the graphic below. The trade names of the transitioned products reflect their manufacturing process, while the NZ denotes the product is manufactured from plasma collected in New Zealand.



In addition:

GAMUNEX® 10% manufactured by Grifols, an intravenous immunoglobulin (IVIg) product will be introduced as an alternative commercial option for patients who do not tolerate PRIVIGEN® NZ / PRIVIGEN® from mid-2023.

KYBERNIN® P (Section 29 Medicine) a commercial CSL Behring antithrombin III concentrate product, will be introduced in early-2024 to replace THROMBOTROL® VF which will no longer be manufactured by CSL Behring.

BIOSTATE® will no longer be supplied in the 500 IU presentation, the 1000 IU will be retained.

Please direct any queries to your local Transfusion Nurse Specialist.

INTRAGAM® P, EVOGAM®, PRIVIGEN® NZ, HIZENTRA® NZ, ALBUMEX® 4, ALBUMEX® 20, ALBUREX® 5 NZ, ALBUREX® 20 NZ, PROTHROMBINEX®-VF, THROMBOTROL®-VF, BIOSTATE®, BERIPLEX® NZ and KYBERNIN® P are registered trademarks of CSL Group of Companies. GAMUNEX® 10% is a registered trademark of Grifols.



Scan here for more information.